UNICANCER
- Country
- 🇧🇷Brazil
- Ownership
- Private
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.unicancer.fr
Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 162
- Registration Number
- NCT05625087
- Locations
- 🇫🇷
CHU Amiens Picardie, Amiens Cedex 1, France
🇫🇷Hôpital Simone Veil de Blois, Blois, France
🇫🇷CHRU Morvan, Brest, France
Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions
- First Posted Date
- 2022-11-18
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 50
- Registration Number
- NCT05622071
- Locations
- 🇫🇷
Hôpital Avicenne, Bobigny, France
🇫🇷Hôpital Michallon, Grenoble, France
🇫🇷Institut Paoli Calmette, Marseille, France
Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 550
- Registration Number
- NCT05617963
- Locations
- 🇫🇷
Institut du Cancer Avignon-Provence, Avignon, France
🇫🇷Centre d'Oncologie du Pays Basque, Bayonne, France
🇫🇷CH de la côte Basque, Bayonne, France
Personalized Medicine for Advanced Biliary Cancer Patients
- Conditions
- Biliary Tract Neoplasms
- Interventions
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 800
- Registration Number
- NCT05615818
- Locations
- 🇫🇷
APHP - Hôpital Paul Brousse, Villejuif, France
🇫🇷Gustave Roussy, Villejuif, France
🇫🇷APHP - Hôpital Cochin, Paris, France
SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers
- Conditions
- Oropharynx Squamous Cell Carcinoma
- Interventions
- Biological: HPV16 Ct-DNA dosing
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 420
- Registration Number
- NCT05582122
- Locations
- 🇫🇷
Institut de cancérologie de Lorraine, Vandœuvre-lès-Nancy, France
🇫🇷Clinique St Vincent- Réunion, Saint-Denis, La Réunion, France
🇫🇷ISC Avignon, Avignon, France
Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer
- Conditions
- Triple Negative Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 96
- Registration Number
- NCT05552001
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer
- Conditions
- Gastric AdenocarcinomaEsophagus AdenocarcinomaGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2022-07-27
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 118
- Registration Number
- NCT05476796
- Locations
- 🇫🇷
CHU d'Estaing, Clermont-Ferrand, France
🇫🇷Institut Andrée Dutreix - Clinique de Flandre, Coudekerque-Branche, France
🇫🇷Clinique de l'Europe, Amiens, France
TARGETed Therapy Drug MONITOring in DIGestive Oncology
- Conditions
- Digestive CancerGISTHepatocellular CarcinomaMetastatic Colorectal CancerNeuroendocrine Tumors
- Interventions
- Other: Blood sampling to build population pharmacokinetics model
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 330
- Registration Number
- NCT05443087
- Locations
- 🇫🇷
CH d'Auxerre, Auxerre, France
🇫🇷Hôpital Beaujon APHP, Clichy, France
🇫🇷Institut Jean Godinot, Reims, France
Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk
- Conditions
- Breast Cancer
- Interventions
- Drug: Anti-aromatase inhibitor
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 696
- Registration Number
- NCT05297617
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de Limoges, Limoges, France
🇫🇷Institute Gustave Roussy, Villejuif, France
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients With Metastatic Cancer in Response After 6 Months of Standard IO
- Conditions
- Lung Cancer MetastaticRenal Cell CarcinomaHead and Neck CancerTriple Negative Breast CancerMerkel Cell CarcinomaHepatocellular CarcinomaMelanomaUrothelial CarcinomaColorectal Carcinoma With Microsatellite InstabilityEsophageal Squamous Cell Carcinoma
- Interventions
- Drug: Reduced dose intensity of IO
- First Posted Date
- 2021-10-14
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- UNICANCER
- Target Recruit Count
- 646
- Registration Number
- NCT05078047
- Locations
- 🇫🇷
CHU Bordeaux - Hôpial Saint André, Bordeaux, France
🇫🇷CH Boulogne sur Mer, Boulogne-sur-Mer, France
🇫🇷GH Mutualiste de Grenoble, Grenoble, France